BR101801 not checked
Boryung Pharmaceutical Co., Ltd
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Peripheral T Cell Lymphoma
- Main trialPhase 2
- “The objective of this phase II study is to evaluate the efficacy and safety of BR101801 in patients with peripheral T-cell lymphoma(PTCL).”In the company’s words, NCT07180771 on ClinicalTrials.gov
- Other names
- Bosmolisib
Other drugs for Peripheral T Cell Lymphoma
- XNW5004Evopoint Biosciences Inc. · Phase 3
- GolidocitinibDizal Pharmaceuticals · Phase 3
- SoquelitinibCorvus Pharmaceuticals, Inc. · Phase 3
- Liposomal mitoxantrone hydrochlorideCSPC · Phase 3
- DuvelisibSecuraBio · Phase 3
- BelinostatAcrotech Biopharma Inc. · Phase 3
Coming up1
- Sep 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Sep 2027 | A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. | |
| Phase 1Completed | 21 Sep 2023 | BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026